LONDON--(BUSINESS WIRE)--According to the latest market study released by Technavio, the global factor VIII deficiency treatment market is projected to grow to USD 11 billion, at a CAGR of close to 6% ...

Hemophilia A is a genetic bleeding disorder caused by a deficiency in clotting factor VIII. Treatment focuses on managing bleeding episode symptoms with clotting factor replacement therapy, ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved efanesoctocog alfa, a once-weekly treatment for children and adults with hemophilia A. The ...

Research and Markets has announced the addition of the "Global Factor VIII Deficiency Treatment Market 2017-2021" report to their offering. The report forecasts the global factor VIII market to grow ...

For people with hemophilia, deficiencies in factor VIII (hemophilia A) or factor IX (hemophilia B) lead to insufficient thrombin generation, which can lead to excessive or spontaneous bleeding. 3,7 In ...

Hemophilia A is characterized by FVIII deficiency, leading to joint bleeds and chronic pain despite prophylactic therapy. Treatment options vary in sustaining FVIII levels, with gene therapy and ...

Patients with the genetic disorder hemophilia A receive factor VIII protein replacement treatments to replenish this clotting protein in their blood, thus preventing dangerous bleeding. Unfortunately, ...

The European Medicines Agency (EMA) this week recommended granting a marketing authorization for Altuvoct (efanesoctocog alfa) for the treatment and prophylaxis of bleeding in patients with hemophilia ...

People with severe hemophilia A are at risk for prolonged bleeding events that can cause serious complications. To prevent these bleeding events, most people with this condition get injections of a ...

Deerfield, Ill., July 25, 2003 -- Baxter Healthcare Corporation announced today that the U.S. Food and Drug Administration (FDA) has approved ADVATE (Antihemophilic Factor (Recombinant), ...